Reviews the current state of obesity pharmacotherapy, emphasizing how GLP-1 receptor agonists and multi-agonists including retatrutide have shifted weight loss toward surgical magnitudes (~15–25%). Discusses mechanisms, patient selection, durability, and the importance of combining pharmacotherapy with lifestyle intervention.
Rubio-Herrera, Miguel A; Mera-Carreiro, Sara